Company Profile

Histogen Inc. is a clinical-stage therapeutics company. The Company is focused on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the bodyâ€™s natural process to restore immune function. Its product candidates include emricasan, CTS-2090 and CTS-2096. It develops emricasan for acute bacterial skin and skin structure infections (ABSSSI) as well evaluating its use for other infectious diseases. Its pipeline also includes novel preclinical product candidates including CTS-2090 and CTS-2096, which are selective small molecule inhibitors of caspase-1 designed for the treatment of certain inflammatory diseases. Emricasan is an orally available pan-caspase inhibitor designed to reduce the activities of human caspases, which are enzymes that mediate inflammation and apoptosis. CTS-2090 and CTS-2096 are selective caspase-1 inhibitors targeting inflammasome activation and to treat a variety of inflammation mediated diseases.

Employees

Sector

Investment Holding Companies

More about the company

24-12-15	Histogen Inc. Went Out of Business	CI
24-12-01	Modified First Amended Liquidation Plan Approved for Histogen Inc.	CI
24-09-30	First Amended Liquidation Plan Filed by Histogen Inc.	CI
24-08-30	Bankruptcy Judge Changed for Histogen Inc.	CI
24-07-14	Liquidation Plan Filed by Histogen Inc.	CI
24-04-19	Subchapter V Trustee Appointed Under Chapter 11 for Histogen Inc.	CI
24-04-18	Histogen Inc. Filed for Bankruptcy	CI
23-11-09	Histogen Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
23-10-04	Histogen Inc.(OTCPK:HSTO) dropped from NASDAQ Composite Index	CI
23-10-03	Histogen Inc. and Allergan Mutually Elect to Terminate the Amended and Restated License Agreement	CI
23-09-22	Histogen Inc.(NasdaqCM:HSTO) dropped from S&P TMI Index	CI
23-09-20	Wall Street Set to Open Wednesday Trading Higher as Investors Await Fed Decision on Interest Rates	MT
23-09-20	Top Premarket Gainers	MT

22-03-29	HC Wainwright Adjusts Histogen's Price Target to $1.50 From $2.40, Reiterates Buy Rating	MT
21-08-30	Histogen : HC Wainwright Starts Histogen at Buy With $2.40 Price Target	MT
21-06-04	Histogen : Canaccord Genuity Adjusts Histogen PT to $4 From $5, Maintains Buy Rating	MT
21-06-04	Histogen : Canaccord Genuity Adjusts Histogen's Price Target to $4 From $5, Reiterates Buy Rating	MT
21-03-04	Histogen : Canaccord Genuity Initiates Coverage on Histogen at Buy Rating, Sets Price Target at $5	MT

24-04-18	Histogen Files for Voluntary Chapter 11 Protection to Facilitate Wind-Down, Maximize Share Offering	AQ
23-12-14	Histogen Announces Second Adjournment of Special Meeting of Stockholders	AQ
23-12-05	Histogen Announces Adjournment of Special Meeting of Stockholders	AQ
23-11-10	Histogen: Q3 Earnings Snapshot	AQ
23-09-18	Histogen Announces Board Approval of Complete Liquidation and Dissolution	AQ

23-07-06	MÄRKTE USA/Schwächer - Robuste Wirtschaftsdaten treiben Zinsen nach oben
23-07-06	MÄRKTE USA/Stark steigende Zinsen schicken Aktien auf Talfahrt
23-07-06	MÄRKTE USA/Schwach - Robuster US-Arbeitsmarkt befeuert Zinssorgen
23-07-06	MÄRKTE USA/Zinssorgen dürften drücken - ADP-Daten belasten Renten
23-04-04	MÄRKTE USA/Wall Street mit leichten Aufschlägen

Date	Insider	Type	Main position	Quantity	% Market Cap.
6/20/23	David Crean	Free	Chairman	6,835	0.1600%
6/20/23	Dan Kisner	Free	Chairman	6,835	0.1600%
6/20/23	Jonathan Jackson	Free	Director	6,835	0.1600%

Histogen Inc. Stock

Stocks

HSTO.Q

US43358Y2028

Investment Holding Companies

Chart: Histogen Inc.

Latest news: Histogen Inc.

Analysts' recommendations: Histogen Inc.

Press Releases: Histogen Inc.

News in other languages: Histogen Inc.

Quotes and Performance

Latest insider transactions

Shell Companies

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
HISTOGEN INC.	+316.67%	+525.00%	-	-	5.34K
CHURCHILL CAPITAL CORP XI	+6.83%	+0.70%	-	-	673M
DRUGS MADE IN AMERICA ACQUISITION II CORP.	-0.05%	0.00%	-	-	648M
BAIN CAPITAL GSS INVESTMENT CORP.	-0.10%	-0.10%	-	-	602M
CHURCHILL CAPITAL CORP XII	-0.98%	-0.80%	-	-	597M
CANTOR EQUITY PARTNERS IV, INC.	-0.29%	-0.14%	+1.72%	-	593M
CENTIEL AG	+2.91%	+11.19%	+285.45%	-74.56%	612M
AMERICAN EXCEPTIONALISM ACQUISITION CORP. A	-0.36%	-2.37%	-	-	551M
CHURCHILL CAPITAL CORP XIII	+0.45%	+1.14%	-	-	512M
Average	+35.25%	+0.17%	+143.59%	-74.56%	598.43M
Weighted average by Cap.	+0.06%	+0.11%	+145.84%	-74.56%